IN 2013, AN ESTIMATED 480 000 patients developed multidrug-resistant tuberculosis (MDR-TB, defined as TB resistant to at least isoniazid and rifampicin); of these, on average 9.0% had extensively drug-resistant TB (XDR-TB, defined as MDR-TB plus resistance to at least one injectable). 1 Although MDR-TB is especially prevalent in Eastern Europe and Central Asia, where up to a third of new TB cases are MDR-TB, it is also increasing in Africa. 1, 2 Treatment regimens recommended by the World Health Organization (WHO) include an injectable agent during the intensive phase (kanamycin [KM] , amikacin [AMK] or capreomycin [CPM] ), a fluoroquinolone (FQ) throughout treatment, and other WHO Group 4 drugs (para-aminosalicylic acid, ethionamide [ETH]/prothionamide [PTH] , cycloserine) or Group 5 drugs (linezolid, clofazimine, imipenem/meropenem, amoxicillin-clavulanate acid, thiacetazone, clarithromycin, high-dose INH), for a total duration of approximately 2 years. Ethambutol (EMB) and pyrazinamide (PZA) can be added, but are not considered effective due to their poor reliability or difficulties with drug susceptibility testing (DST). 3 These recommendations are mainly based on expert opinion and cohort analysis, including a metaanalysis of individual patient data. Only 40-70% of patients achieve treatment success due to poor efficacy and poor adherence. 1, [4] [5] [6] [7] Two drugs, bedaquiline (BDQ) and delamanid (DLM), have been conditionally approved by the US Food and Drug Administration and/or the European Medicines Agency for treatment of MDR-TB. Due to limited data on their long-term efficacy and safety, these drugs have been added to the list of WHO Group 5 drugs. The WHO recommends considering the addition of BDQ or DLM when an MDR-TB regimen with four effective drugs, including an FQ and an injectable agent in addition to PZA, cannot be designed (additional resistance to FQ or an injectable agent, drug intolerance or contraindication). DLM may also be added for patients at higher risk of poor outcomes. [8] [9] [10] However, current guidelines do not detail the characteristics of patients at increased risk.
We present the results of a multisite, retrospective cohort analysis of MDR-TB patients treated in programmes supported by Médecins Sans Frontières (MSF) in five countries: Abkhazia, Georgia; Armenia, Karakalpakstan Region, Uzbekistan; Nairobi, Kenya; and Shiselweni Region, Swaziland. Four of the five programmes (Abkhazia, Armenia, Karakalpakstan and Shiselweni) are in high MDR-TB burden countries, with MDR-TB prevalence among new cases (2011) of between 7.7% in Swaziland and 23.2% in Armenia. 1, 11, 12 Four programmes have been approved by the WHO Green Light Committee (GLC) since 2004 for Abkhazia, 2003 for Karakalpakstan and Armenia and 2009 for Shiselweni. 11, 13 The programme in Nairobi has not applied for GLC approval to date.
Our primary objective was to determine the odds of unfavourable outcomes to identify patients who could benefit from the addition of the new drugs. 9, 10 Secondary objectives were to describe the treatment outcomes and the extension of drug resistance to FQs and injectable agents during treatment. Exploratory objectives assessed the effectiveness of treatment recommendations, such as the use of KM as the first-choice injectable agent, the addition of EMB or PZA to a regimen already including four effective drugs, and the prescription of a thioamide in preexposed patients. 
METHODS

Patient management
Treatment regimens were individualised using four or five likely effective drugs for a duration of 15-24 months, administered under observation with psychosocial support and careful management of adverse events. 14 During the early years of the programmes in Abkhazia, Armenia and Karakalpakstan, patients were hospitalised during the intensive phase; in later years, patients were discharged for ambulatory treatment after smear conversion. In Nairobi and Shiselweni, treatment was ambulatory unless hospitalisation was clinically indicated. Monthly culture and DST were performed in quality-assured laboratories or in supranational laboratories.
Inclusion, outcome definitions and covariate definitions
The study included all patients aged 718 years with a baseline DST result confirming MDR-TB (sample collected either before starting MDR-TB treatment or 61 month after commencement). To account for the 2-year duration of the WHO regimen and delays in data entry, analysis of outcomes was limited to patients started on treatment up to 31 December 2009. The administrative censoring date of the database was 31 December 2011.
Clinicians used the 2008 WHO definitions of treatment outcomes requiring at least five consecutive negative culture results during the final 12 months of treatment to be classified as cured, and either 72 positive results among the five cultures recorded in the final 12 months, one positive in any one of the final three cultures, or a clinical decision to discontinue treatment early due to failure. 3 Favourable outcome was defined as a combination of cured and treatment completed, and unfavourable outcome as a combination of death and failure. Drug resistance extension was defined as resistance to drugs (OFX, KM, CPM) that had not been detected at baseline.
The following patient characteristics were recorded at treatment initiation: age; sex; history of incarceration; history of MDR-TB contact; daily alcohol consumption (none, ,5 drinks and 75 drinks); comorbidities (known diabetes, human immunodeficiency virus infection [HIV]); past TB treatment history, defined as new cases (,1 month of antituberculosis treatment), previously treated cases (first-and second line anti-tuberculosis drugs); body mass index (BMI) (low ,18.5 kg/m 2 ); presence of cavities on chest radiograph; sputum smear microscopy results (negative, low [scanty or 1þ] and high bacillary load [2þ or 3þ]); and DST results. TB strain resistance profiles were defined as MDR-TB with DST to second-line drugs not known; simple MDR-TB (no resistance to OFX and an injectable agent); pre-XDR-TB one injectable agent (resistance to either KM or CPM and OFX-susceptible); pre-XDR-TB two injectable agents (resistance to KM and CPM and OFX-susceptible); pre-XDR-TB OFX (resistance to OFX and susceptibility to both KM and CPM); and XDR-TB. Other covariates were drug prescription at treatment initiation regardless of duration, number of drugs prescribed and incidence of treatment interruption of any duration per year of treatment due to side effects or patient reasons (social, refusal, travel).
Data management and analysis
Data were recorded in the standardised Koch 6 database (Koch 6 software, Médecins Sans Frontières [MSF], Paris, France). In Karakalpakstan, an Epi Info database (Centers for Disease Control and Prevention, Atlanta, GA, USA) was used. The primary analysis of predictors of unfavourable outcomes was performed for all patients started on treatment, after exclusion of patients transferred out before the end of treatment or those still on treatment at analysis. Sensitivity analyses included a complete case analysis classifying patients lost to follow-up as unfavourable outcomes, a failure only analysis and a death only analysis. Secondary analyses described the treatment outcomes and the proportion of patients with drug resistance extension stratified by baseline drug resistance profiles. To describe the role of KM, CPM, EMB, PZA and ETH, exploratory analyses presented treatment outcomes stratified by individual drug resistance at baseline and previous drug exposure, and compared the success rates in patients who were not lost to follow-up.
Patient characteristics were summarised using frequencies and percentages for categorical variables, and median and interquartile ranges (IQRs) for continuous variables. The percentage of patients with drug resistance extension was calculated for those patients with a TB strain with baseline susceptibility to a drug and at least one culture result during followup. Univariate and multivariate random-intercept logistic regression was fitted to explore the link between patients and treatment characteristics and unfavourable outcomes. Missing values were introduced as a separate category in the model to keep the full sample size. Predictors were systematically adjusted on programme location (random-intercept) and period of inclusion (2001-2005, 2006-2007, 2008-2009 ). Covariates associated with P , 0.4 in univariate analysis were included in the initial multivariate model; a manual backward stepwise approach was used to obtain the final multivariate model. Statistical significance (P , 0.05) was assessed using the likelihood-ratio test. Analyses were performed using Stata 12.1 software (Stata Corporation, College Station, TX, USA).
Ethics approval
The study was approved by all the relevant health ministries. This retrospective study meets the criteria of the MSF Ethics Review Board for exemption from ethics review.
RESULTS
Patient characteristics
Of 1834 drug-resistant patients enrolled, 401 (21.9%) were excluded from the analysis. Most of the included patients (1355/1433, 94.6%) were from programmes in Eastern Europe and Central Asia, and 82.4% had been previously treated for TB, 10.8% of whom had received second-line anti-tuberculosis drugs. Resistance to EMB and PZA were reported in respectively 82.2% and 59.0% of the patients tested. Among 1243 patients with second-line DST results, respectively 817 (65.7%), 339 (31.3%) and 37 (3.0%) had simple MDR-TB (no resistance to an injectable agent and/or FQ), pre-XDR-TB and XDR-TB at baseline. Resistance to second-line anti-tuberculosis drugs was more frequent in the Eastern European and Central Asian sites than in African sites (Table 1) . At treatment initiation, patients received a median of 5 (IQR 5-6) anti-tuberculosis drugs.
Predictors of unfavourable outcomes
Overall, 808/1433 (56.4%) patients achieved treatment success, 292 (20.4%) had an unfavourable outcome and 333 (23.2%) were lost to follow-up (Table 2) . Past incarceration, a history of antituberculosis treatment with first-or second-line antituberculosis drugs, low BMI, high bacillary load, and a TB strain with pre-XDR-TB specifically resistant to two injectable agents, pre-XDR-TB OFX, or XDR-TB compared with simple MDR-TB were independently associated with an unfavourable outcome ( Table 3 ).
In the complete case sensitivity analysis, HIV infection (adjusted odds ratio [aOR] 4.68, 95% confidence interval [CI] 1.34-16.32) was also associated with an unfavourable outcome (Appendix).* Treatment history with second-line anti-tuberculosis drugs (aOR 5.34, 95%CI 2.27-13.53), low BMI (aOR 2.17, 95%CI 1.39-3.33), high sputum bacillary load (aOR 4.69, 95%CI 1.55-14.14), and XDR-TB vs. simple MDR-TB (aOR 3.59, 95%CI 1.37-9.45) were associated with death. In the failure only analysis, past incarceration, history of anti-tuberculosis treatment and high bacillary load were no longer associated (Appendix). Variance due to sites represented 1.3% of the total variance, suggesting low heterogeneity between the sites.
Treatment outcomes and resistance extension by baseline drug resistance profile Treatment success ranged between 59.7% in patients without second-line resistance to 27.0% in XDR-TB patients (Table 2) . Among simple MDR-TB patients with at least one follow-up DST result (n ¼ 744), DST later revealed drug resistance extension to KM (15.2%), CPM (9.1%) and OFX (12.1%) and to XDR-TB in 5.6% (Table 4) . Among pre-XDR-TB patients, 18.8% (73/350) became XDR-TB. Drug resistance extension to an injectable agent or OFX was associated with an unfavourable outcome (Table  3) , while drug resistance extension to OFX (aOR 3.13, 95%CI 1.70-5.77) was associated with death (Appendix).
Role of kanamycin, capreomycin, ethambutol, pyrazinamide and ethionamide The risk of an unfavourable outcome was increased by 54% with prescription of CPM rather than KM (Table 3) . Among patients with a TB strain susceptible to both injectable agents, success was higher in those initiated on KM rather than CPM (82.6% vs. 74.2%, P ¼ 0.013). Among those patients susceptible to both drugs, 229/360 (63.6%) started on CPM were switched to KM when KM susceptibility was confirmed. The proportion who switched was similar between patients with an unfavourable outcome and those with favourable outcomes (63/99, 63.6% vs. 166/271, 61.2%, P ¼ 0.676). Among patients susceptible to EMB at baseline, treatment success rates did not differ between those who were prescribed EMB and those who were not. Similar results were found with PZA; however, only 33.6% of patients underwent DST against PZA (Table 5) . Among patients who were ETH-susceptible at baseline, those previously exposed to ETH had lower treatment success rates than those who were never exposed (43.7% vs. 77.3%). Patients who did not receive ETH/PTH in their initial prescription (aOR 2.07, 95%CI 1.08-3.99) were more likely to die (Appendix).
DISCUSSION
This is one of the largest reported multisite cohorts of MDR-TB patients using data from GLC-approved programmes. Our analysis confirms the poor effectiveness of treatment regimens for MDR-TB and drug resistance extension. 13, 15, 16 In addition to programmatic challenges, the use of long, poorly effective and badly tolerated regimens increases the risk of loss to follow-up. 17 Unsurprisingly, resistance to an injectable agent and/or FQ was a risk factor for poor outcome. 7, 13, 18, 19 Previous exposure to anti-tuberculosis drugs, low BMI and high bacillary load (72þ) were also risk factors for unfavourable outcomes in our study, as previously reported. 5, 19 Our findings confirm those from meta-analyses showing no benefit, and only an unnecessary increase in pill burden, in the systematic addition of EMB to MDR-TB treatment, even in patients with an EMBsusceptible strain. 6, 21, 22 They also suggest no additional benefit of systematically adding PZA to the 23 The significant reduction in numbers of deaths among patients started on ETH/PTH was unexpected, but consistent with previous cohorts. 18, 19 The higher proportion of unfavourable outcomes in patients with ETH-susceptible strains who were previously exposed to ETH/ PTH than non-exposed patients may just reflect the poor reliability of DST for these drugs. 24 Almost a quarter of the MDR-TB patients in our cohort were resistant to OFX or two injectable agents, and would be eligible for BDQ or DLM. 9, 10 However, patients at high risk of poor outcome and who could also benefit from the prescription of DLM represented a much higher proportion. 9 Considering only BMI ,18.5 kg/m 2 and high bacillary load at treatment initiation-both factors associated with poor outcomes in our study and in previous studiesrespectively 48.5% and 72.9% of patients presented these characteristics. 5, 19 These figures go far beyond the 20% estimated target of MDR-TB patients with DLM by 2020 announced by Otsuka et al. at the 2015 WHO GLI/GDI (Global Laboratory Initiative/ Global Drug-Resistant TB Initiative) Partners Forum. 25 We also identified potential differences in treatment effectiveness between KM and CPM, which has not been previously reported. KM seemed more effective than CPM in patients whose isolates were susceptible to both drugs, and the effect remained after adjustment for patient comorbidities, treatment history, baseline drug resistance profiles and prescription of FQ. These findings support the selection of KM as the injectable agent of choice. They also indicate that it may be beneficial to switch patients already on CPM to KM if DST shows KM susceptibility. If the superiority of KM is confirmed, this would be especially important for countries with limited resources, given the lower cost of KM (USD2.58/g) compared with CPM (USD4/g) and the poor availability of CPM. 21, 26 Compared to the meta-analysis of individualised patient data, our study results were obtained from programmes using the same treatment strategies and the same data recording system, which reduced the variability between sites and gave us the possibility to adjust for more covariates, such as comorbidities, disease severity and treatment tolerability. 6, 7, 18, 27 As the overlap with the recent meta-analysis was limited to 77 patients from Karakalpakstan, the present study describes a new, large population. 6, 7, 18, 27 The study has several limitations. First, due to its complexity, DST against PZA was only performed in 33.6% of patients based on clinician's request in supranational laboratories. Missing PZA DST results were not equally distributed among risk factors of unfavourable outcomes (data not shown), and might have biased the effect of resistance to PZA on treatment outcome.
Second, most patients not tested for HIV were from the Eastern European or Central Asian regions. This could explain the association between unknown HIV test result and unfavourable outcomes in the univariate analysis, as patients from these regions were more likely to be infected with XDR-TB or a pre-XDR-TB strain. The association disappeared after adjustment for these factors. The loss of association between HIV infection and unfavourable outcomes after multivariate analysis could be explained by the very low number of patients with HIV results. Third, treatment interruptions for patient reasons were used as a proxy for adherence to compensate for the absence of adherence data (not collected) from the site in Swaziland. This did not allow appropriate adjustment for treatment adherence.
Fourth, the prescription of drugs was only considered at treatment initiation. This did not reflect the real effect of the drug on treatment outcomes, as the initial prescription might be changed during treatment due to poor tolerability or based on DST results. Specifically, the effect of switching patients between CPM and KM after receiving the DST results could not be assessed.
Fifth, drug resistance amplification could not be described due to lack of genotyping evidence. Results of drug resistance extension and its effect on treatment outcomes should be interpreted with caution, keeping in mind that reasons other than amplification could explain the increase in resistance.
Sixth, most patients were from the Eastern European or Central Asian regions, which may limit the generalisability of these results to other regions. However, the predictor analysis was systematically adjusted for programme location.
Seventh, the P value was not corrected or adjusted despite the risk of increased type I error resulting from multiple comparisons in the multivariate logistic model. The interpretation of the findings should be based more on the ORs and their CIs rather than on the P values.
Finally, due to the retrospective study design based on routinely collected data, we did not have sufficiently repeated measurements of time-dependent variables to perform a marginal structural model to account for the time-dependent nature of confounders (drug resistance extension, treatment change). Time-dependent confounders might therefore lead to biased estimates of exposure effects. However, when removing time-dependent confounders (drug resistance extension, incidence of interruption due to side effects) from the multivariate model, we found similar estimates for baseline variables on outcome (data not shown).
CONCLUSION
We identified some patient characteristics that were associated with higher risk of poor outcome and which could guide the prescription of new drugs when designing an MDR-TB regimen. In our study settings, up to two thirds of MDR-TB patients are likely to benefit from the new drugs, especially DLM. Other risk factors for poor outcome may exist in other settings and more studies are needed. Our study results also support the prescription of KM as the injectable agent of choice. 
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